SCHEMBL1976949

SCHEMBL1976949

CCNC(=O)c1ccc(O)cn1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.47
PARP1 P09874 1/20 0.45
MAOB P27338 1/20 0.45
EGLN1 Q9GZT9 2/20 0.44
DEGS1 O15121 2/20 0.44
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
USP7 Q93009 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19289588 0.86 TP53 (0.54) MAOBKDM4EL3MBTL1
SCHEMBL9561524 0.82 ALDH1A1 (0.51) CNR1KDM4ELMNA
SCHEMBL10228354 0.82 CNR1 (0.57) CNR1PARP1MAOBEGLN1KDM4E
SCHEMBL3485307 0.81 CNR2 (0.43) MAOBEGLN1DEGS1
SCHEMBL23708908 0.81 CNR1 (0.46) CNR1PARP1MAOBEGLN1PSEN1
SCHEMBL17055348 0.81 MAOB (0.47) CNR1PARP1MAOBEGLN1KDM4E
SCHEMBL9908372 0.81 PARP1 (0.53) CNR1PARP1MAOBEGLN1KDM4E
SCHEMBL285908 0.81 KDM4E (0.55) CNR1PARP1MAOBEGLN1KDM4E
SCHEMBL2645831 0.79 USP7 (0.50) CNR1PARP1DEGS1KDM4ELMNA
SCHEMBL8282027 0.79 P2RX7 (0.52) MAOBDEGS1USP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609699-B2 Oxotetrahydrofuran-2-yl-benzimidazole derivative MSD K.K. (JP) 2013-12-17 US disclosed
EP-2328892-B1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2013-01-16 EP disclosed
US-20110144162-A1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-16 US disclosed
EP-2328892-A1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE MSD K.K. (JP) 2011-06-08 EP disclosed
WO-2010024110-A1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144162-A1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE GCK, GCKR, KHK CNR1 1858/4885PARP1 3352/4885MAOB 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.